PRO-ACT Study Shows Better Outcomes with Minoxidil PRCT for Androgenetic Alopecia

A recent clinical study has highlighted the potential of a novel Minoxidil formulation integrated with bioactive peptides for the management of androgenetic alopecia (AGA). The formulation combines Minoxidil 5% with Procapil, Redensyl, Caffeine, and Transcutol (Minoxidil PRCT) and has demonstrated improved clinical outcomes compared to plain Minoxidil 5%.

The PRO-ACT study, published in the September 2025 issue of the Indian Journal of Clinical and Experimental Dermatology, was an open-label, prospective, real-world study conducted across 14 centres in India over a four-month period. A total of 400 patients with androgenetic alopecia, aged 32–40 years, were enrolled and equally divided into two groups. One group received the Minoxidil PRCT formulation while the other was treated with plain Minoxidil 5%, applied topically at a dose of 1 ml to affected scalp areas. Primary outcomes included changes in hair diameter and terminal and vellus hair density assessed through trichoscopy.

The Minoxidil PRCT group showed a greater increase in hair diameter (+4.8 µm) compared to the plain Minoxidil group (+2.7 µm). Improvements in terminal and vellus hair density were also higher with PRCT. Importantly, patient satisfaction, treatment compliance, and tolerability were significantly better in the PRCT group, with fewer adverse events reported. These findings suggest that combining Minoxidil with bioactive peptides may offer a more effective and patient-friendly approach to AGA management.